Document Detail

Residual viability is a predictor of the perfusion enhancement obtained with the cell therapy of chronic myocardial infarction: a pilot multimodal imaging study.
MedLine Citation:
PMID:  22785499     Owner:  NLM     Status:  In-Data-Review    
PURPOSE: Up to now, there has been limited investigation into cell therapy in the chronic phase of severe myocardial infarction (MI), and many questions remain concerning the contribution of the engrafted cells and especially their impact on the reperfusion of MI areas, when assessed by objective quantitative imaging techniques. This randomized pilot SPECT, PET, and MRI study was aimed at assessing the effects of bone marrow mononuclear cells (BMNCs) when implanted in areas of severe and chronic MI.
MATERIALS AND METHODS: Fourteen patients, who were referred for coronary artery bypass grafting (CABG) and in whom a screening MIBI-SPECT revealed severely damaged myocardium (<50% uptake under nitrate), were randomized between a cell therapy group (n = 7; CABG and injection of BMNCs within MI areas) and a control group (n = 7; CABG alone).
RESULTS: The MI areas exhibited a posttherapeutic enhancement in the rest-uptake of MIBI in the cell therapy group [difference between 6-month control and baseline: +6.8% (5.4%), P = 0.03] but not in the control group [+1.0% (4.3%)]. However, in a per-patient analysis, this improvement was significant (> +9%) in only 3 cell therapy patients, whose MI areas before therapy had a higher FDG uptake [59% (9%) vs 38% (8%), P = 0.03] and a lower transmural extent at MRI [40% (6%) vs 73% (18%), P = 0.03] when compared with the other cell therapy patients.
CONCLUSIONS: Perfusion enhancement, obtained with BMNCs in areas of chronic MI, might require an intermediate level of viability documented with FDG-PET and MRI and that totally necrotic MI seems refractory to this cell therapy technique.
Pablo Maureira; Nguyen Tran; Wassila Djaballah; Michaël Angioï; Danièle Bensoussan; Nicolas Didot; Renaud Fay; Nicolas Sadoul; Jean-Pierre Villemot; Pierre-Yves Marie
Related Documents :
21947989 - Effects of levosimendan without loading dose on systolic and diastolic function in pati...
11710789 - Calcium channel blockers in hypertension: reappraisal after new trials and major meta-a...
21835319 - Electrocardiographic comparison of ventricular arrhythmias in patients with arrhythmoge...
1529899 - Fibrin (ogen)-derived peptide b beta 30-43 is a sensitive marker of activated neutrophi...
21700089 - Monomorphic ventricular tachycardia and mediastinal adenopathy due to granulomatous inf...
21934609 - Plasma myeloperoxidase concentration predicts the presence and severity of coronary dis...
20961829 - Modification of a hybrid technique for closure of muscular ventricular septal defects i...
17670449 - Internal mammary revascularization in patients with variant angina and normal coronary ...
15683109 - Early assessment of myocardial contractility by contrast-enhanced magnetic resonance (c...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical nuclear medicine     Volume:  37     ISSN:  1536-0229     ISO Abbreviation:  Clin Nucl Med     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-07-12     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7611109     Medline TA:  Clin Nucl Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  738-42     Citation Subset:  IM    
From the *Department of Cardio-Vascular Surgery, CHU-Nancy; †School of Surgery, Faculty of Medicine, Nancy University; ‡INSERM, U961; §Department of Nuclear Medicine, CHU-Nancy; ∥INSERM, U947; ¶Department of Cardiology and #Unit of Cell Transplantation and Tissue, CHU-Nancy; and **INSERM, Centre d'Investigation Clinique CIC-P 9501, Nancy, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Outpatient 131I-Rituximab Radioimmunotherapy for Non-Hodgkin Lymphoma: A Study in Safety.
Next Document:  The Influence of Residual Nor-?-CFT in 11C CFT Injection on the Parkinson Disease Diagnosis: A 11C C...